靶向高密度脂蛋白的动脉粥样硬化防治研究:从升高水平到改善功能

Current research progress in HDL based atherosclerosis prevention and therapy: from quantity increase to quality improvement

动脉粥样硬化(atherosclerosis,AS)是一种血管炎症性病变,是心肌梗死和脑卒中的重要原因。预计到2020年,AS将成为世界范围内首要致死病因。AS的防治策略研究一直是心血管领域的研究重点,而高密度脂蛋白(high density lipoprotein,HDL)因具有良好的抗AS作用一直被认为是药物开发的靶点。本综述将重点讨论目前增加血浆HDL水平和改善其功能的药物研发策略以及它们的可行性和局限性,同时就HDL新药物研究加以展望。

Atherosclerosis (AS) is the major etiology for myocardial infarction and stroke, which is projected to be the greatest killer by 2020. Strategies to prevent AS have been intensively studied in recent years. High density lipoprotein ( HDL) is considered one of the most important therapeutic targets as it functions in a critical manner in the pathogenesis of AS and negatively correlates with incidence. In this review, therefore, we summarize the progress of drug development targeting HDL, focusing on feasibility and limitations. Moreover, we provide our perspectives related to challenges and opportunites related to AS and mediation and/or modulation of HDL.